RNTX
Rein Therapeutics IncNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$88.11M
P/E Ratio
—
EPS
$-1.90
Beta
1.42
52W High
$2.21
52W Low
$0.95
50-Day MA
$1.34
200-Day MA
$1.30
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About Rein Therapeutics Inc
Rein Therapeutics Inc (RNTX) is an innovative biopharmaceutical company committed to developing cutting-edge therapies for neurodegenerative disorders utilizing its proprietary technology platform that integrates advanced neuroscience with drug development. The company’s strong pipeline reflects its strategic focus on addressing significant unmet medical needs, facilitated by a seasoned leadership team with extensive industry experience. Operating within a rapidly evolving therapeutic landscape, Rein Therapeutics presents a compelling opportunity for institutional investors seeking exposure to transformative healthcare solutions.
Fundamentals
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | 0 |
| EBITDA | $-21.57M |
| Operating Margin | 0.00% |
| Return on Equity | -163.40% |
| Return on Assets | -32.10% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $-1.19 |
| Price-to-Book | 28.17 |
| Price-to-Sales (TTM) | — |
| EV/Revenue | - |
| EV/EBITDA | -0.64 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $85.54M |
| Float | $72.52M |
| % Insiders | 6.79% |
| % Institutions | 13.37% |
Historical Volatility
HV 10-Day
67.68%
HV 20-Day
134.49%
HV 30-Day
122.06%
HV 60-Day
102.50%
HV Rank
93.7%
Volatility is currently contracting
Analyst Ratings
Consensus ($10.00 target)
1
Buy1
HoldMore HEALTHCARE Stocks
Data last updated: 5/25/2026